Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and expression

Journal of Pharmacology and Experimental Therapeutics

Volumn 341, Issue 1, 2012, Pages 294-305

  Temesvári, Manna ^a   Kóbori, László ^b   Paulik, Joźsef ^c   Saŕvaŕy, Eniko ^b   Belic, Ales ^d   Monostory, Katalin ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c Nucleotest Bio Ltd   (Hungary)

^d UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; MEPHENYTOIN; MESSENGER RNA; MIDAZOLAM; NIFEDIPINE; PHENACETIN; TACROLIMUS; TOLBUTAMIDE;

ARTICLE; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG METABOLIZING CAPACITY; DRUG OXIDATION; ENZYME ACTIVITY; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE; LIVER METABOLISM; PHENOTYPE; POPULATION RESEARCH; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENOTYPE; HUMANS; MALE; MICROSOMES, LIVER; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; YOUNG ADULT;

EID: 84858645160     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.189597     Document Type: Article

References (34)

1. Blanco JG, Harrison PL, Evans WE, and Relling MV (2000) Human cytochrome P450 maximal activities in pediatric versus adult liver. Drug Metab Dispos 28:379-382. (Pubitemid 30185673)
2. Brockmöller J, Kirchheiner J, Meisel C, and Roots I (2000) Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics 1:125-151.
3. Butler MA, Iwasaki M, Guengerich FP, and Kadlubar FF (1989) Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci U S A 86:7696-7700. (Pubitemid 19265255)
4. Chen Q, Zhang T, Wang JF, and Wei DQ (2011) Advances in human cytochrome p450 and personalized medicine. Curr Drug Metab 12:436-444.
5. Dai Y, Hebert MF, Isoherranen N, Davis CL, Marsh C, Shen DD, and Thummel KE (2006) Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 34:836-847.
6. Finnström N, Thörn M, Lööf L, and Rane A (2001) Independent patterns of cytochrome P450 gene expression in liver and blood in patients with suspected liver disease. Eur J Clin Pharmacol 57:403-409. (Pubitemid 33787191)
7. Furukawa M, Nishimura M, Ogino D, Chiba R, Ikai I, Ueda N, Naito S, Kuribayashi S, Moustafa MA, Uchida T, et al. (2004) Cytochrome p450 gene expression levels in peripheral blood mononuclear cells in comparison with the liver. Cancer Sci 95:520-529. (Pubitemid 38832702)
8. George J, Liddle C, Murray M, Byth K, and Farrell GC (1995) Pre-translational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis. Biochem Pharmacol 49:873-881.
9. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, and Waxman DJ (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051-5060. (Pubitemid 17204301)
10. Heyn H, White RB, and Stevens JC (1996) Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin. Drug Metab Dispos 24:948-954. (Pubitemid 26314545)
11. Huang W, Lin YS, McConn DJ 2nd, Calamia JC, Totah RA, Isoherranen N, Glodowski M, and Thummel KE (2004) Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 32:1434-1445. (Pubitemid 39564564)
12. Ingelman-Sundberg M (2001) Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med 250:186-200.
13. Kabanova S, Kleinbongard P, Volkmer J, Andrée B, Kelm M, and Jax TW (2009) Gene expression analysis of human red blood cells. Int J Med Sci 6:156-159.
14. Koch I, Weil R, Wolbold R, Brockmöller J, Hustert E, Burk O, Nuessler A, Neuhaus P, Eichelbaum M, Zanger U, et al. (2002) Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 30:1108-1114.
15. Kronbach T, Mathys D, Gut J, Catin T, and Meyer UA (1987) High-performance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal Biochem 162:24-32. (Pubitemid 17064298)
16. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, and Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36:89-96. (Pubitemid 19191264)
17. Lee CY, Lai TY, Wu YM, Hu RH, Lee PH, Hsu LC, and Tsai MK (2010) Gene expression of P-glycoprotein and cytochrome P450 3A4 in peripheral blood mononuclear cells and correlation with expression in liver. Transplant Proc 42:834-836.
18. Lewis DF (2004) 57 varieties: the human cytochromes P450. Pharmacogenomics 5:305-318.
19. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
20. Miners JO and Birkett DJ (1996) Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9. Methods Enzymol 272:139-145. (Pubitemid 26299876)
21. Monostory K and Pascussi J-M (2008) Regulation of drug-metabolizing human cytochrome P450s. Acta Chim Slo 55:20-37.
22. Niwa T, Shiraga T, Yamasaki S, Ishibashi K, Ohno Y, and Kagayama A (2003) In vitro activation of 7-benzyloxyresorufin O-debenzylation and nifedipine oxidation in human liver microsomes. Xenobiotica 33:717-729. (Pubitemid 36960258)
23. Nowakowski-Gashaw I, Mrozikiewicz PM, Roots I, and Brockmöller J (2002) Rapid quantification of CYP3A4 expression in human leukocytes by real-time reverse transcription-PCR. Clin Chem 48:366-370. (Pubitemid 34107279)
24. Patki KC, Von Moltke LL, and Greenblatt DJ (2003) In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3A4 and cyp3A5. Drug Metab Dispos 31:938-944. (Pubitemid 36759065)
25. Rodríguez-Antona C, Donato MT, Pareja E, Gómez- Lechón MJ, and Castell JV (2001) Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme activity. Arch Biochem Biophys 393:308-315.
26. Shu Y, Cheng ZN, Liu ZQ, Wang LS, Zhu B, Huang SL, Ou-Yang DS, and Zhou HH (2001) Interindividual variations in levels and activities of cytochrome P-450 in liver microsomes of Chinese subjects. Acta Pharmacol Sin 22:283-288. (Pubitemid 32221503)
27. Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C, Ihrie P, Mehall JM, Edwards TL, and Dawson EP (2004) Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 5:895-931. (Pubitemid 39386756)
28. Srivastava PK, Yun CH, Beaune PH, Ged C, and Guengerich FP (1991) Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4′-hydroxylase cytochrome P-450 enzymes. Mol Pharmacol 40:69-79.
29. Sumida A, Kinoshita K, Fukuda T, Matsuda H, Yamamoto I, Inaba T, and Azuma J (1999) Relationship between mRNA levels quantified by reverse transcription-competitive PCR and metabolic activity of CYP3A4 and CYP2E1 in human liver. Biochem Biophys Res Commun 262:499-503. (Pubitemid 29429896)
30. Thörn M, Lundgren S, Herlenius G, Ericzon BG, Lööf L, and Rane A (2004) Gene expression of cytochromes P450 in liver transplants over time. Eur J Clin Pharmacol 60:413-420. (Pubitemid 39214895)
31. Transon C, Lecoeur S, Leemann T, Beaune P, and Dayer P (1996) Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes. Eur J Clin Pharmacol 51:79-85. (Pubitemid 26300938)
32. van der Hoeven TA and Coon MJ (1974) Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes. J Biol Chem 249:6302-6310.
33. Wilke RA, Musana AK, and Weber WW (2005) Cytochrome P450 gene-based drug prescribing and factors impacting translation into routine clinical practice. Personalized Med 2:213-224.
34. Yuan R, Madani S, Wei XX, Reynolds K, and Huang SM (2002) Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 30:1311-1319. (Pubitemid 35397032)